Evidence map›Paper›PMID 35358221›Full record

ArticlePloS one2022

Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.

Laura J Rojas, Mohamad Yasmin, Jacquelynn Benjamino, Steven M Marshall, Kailynn J DeRonde, Nikhil P Krishnan, Federico Perez, Andrew A Colin, Monica Cardenas, Octavio Martinez and 12 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. The Impact ofPathogens (Basel, Switzerland) · 2023
    Article
  9. Article
  10. Article
  11. In host evolution of beta lactam resistance during active treatment forFrontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 2 countries.

Laura J RojasDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Mohamad YasminResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, United States of America.
Jacquelynn BenjaminoThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Steven M MarshallResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, United States of America.
Kailynn J DeRondeJackson Memorial Hospital, Jackson Health System, Miami, Florida, United States of America.
Nikhil P KrishnanCenter for Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Federico PerezMedical Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States of America.
Andrew A ColinDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Monica CardenasDepartment of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
Octavio MartinezJackson Memorial Hospital, Jackson Health System, Miami, Florida, United States of America.
Armando Pérez-CardonaJackson Memorial Hospital, Jackson Health System, Miami, Florida, United States of America.
Daniel D RhoadsDepartment of Laboratory Medicine and Infection Biology Program, Cleveland Clinic, Cleveland, Ohio, United States of America.
Michael R JacobsDepartment of Pathology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University Cleveland, Ohio, United States of America.
John J LiPumaDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Michael W KonstanDepartment of Pediatrics, Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States of America.
Alejandro J VilaInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario, Argentina.
Andrea SmaniaCONICET, Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), Córdoba, Argentina.
Andrew R MackDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.ORCID 0000-0002-0131-7996
Jacob G ScottCenter for Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Mark D AdamsThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Lilian M AbboJackson Memorial Hospital, Jackson Health System, Miami, Florida, United States of America.
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.ORCID 0000-0002-3299-894X
Louis Stokes Cleveland VA Medical Center · USUniversity of Miami · USCleveland Clinic · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARJackson Laboratory · USJackson Memorial Hospital · USCleveland Clinic Lerner College of Medicine · USGeriatric Research Education and Clinical Center · USRainbow Babies & Children's Hospital · USUniversity of Michigan · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
BLRD VA I01 BX001974NCATS NIH HHS UL1 TR002548NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560
6 · The paper itself

Abstract

backgroundPseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young female CF patient who underwent double lung transplantation. Our goal was to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence evolution over time.

methodsTwenty-two sequential P. aeruginosa isolates were obtained within a 17-month period, before and after a double-lung transplant. At the end of the study period, antimicrobial susceptibility testing, whole genome sequencing (WGS), phylogenetic analyses and RNAseq were performed in order to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence changes over time.

resultsThe majority of isolates were resistant to almost all tested antibiotics. A phylogenetic reconstruction revealed 3 major clades representing a genotypically and phenotypically heterogeneous population. The pattern of mutation accumulation and variation of gene expression suggested that a group of closely related strains was present in the patient prior to transplantation and continued to change throughout the course of treatment. A trend toward accumulation of mutations over time was observed. Different mutations in the DNA mismatch repair gene mutL consistent with a hypermutator phenotype were observed in two clades. RNAseq performed on 12 representative isolates revealed substantial differences in the expression of genes associated with antibiotic resistance and virulence traits.

conclusionsThe overwhelming current practice in the clinical laboratories setting relies on obtaining a pure culture and reporting the antibiogram from a few isolated colonies to inform therapy decisions. Our analyses revealed significant underlying genomic heterogeneity and unpredictable evolutionary patterns that were independent of prior antibiotic treatment, highlighting the need for comprehensive sampling and population-level analysis when gathering microbiological data in the context of CF P. aeruginosa chronic infection. Our findings challenge the applicability of antimicrobial stewardship programs based on single-isolate resistance profiles for the selection of antibiotic regimens in chronic infections such as CF.

Indexed as

Cystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsDrug Resistance, MultipleFemaleHumansMicrobial Sensitivity TestsPhylogenyPseudomonas aeruginosaAnti-Bacterial Agents

Identifiers

PMID35358221
PMCPMC8970513
OpenAlexW4220746807

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.